The Effect of Probiotics on E. Coli-induced Gastroenteritis

NCT01709266 | Completed

• 1 other identifier: NL40301.081.12
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Background: The incidence of gastrointestinal infections is very high. In Western countries at least 30% of the population suffers from at least one food-borne infection per year. Mostly because of the problem of antibiotic resistance, more emphasis is put on prevention of infections. One of the possibilities is to strengthen human resistance to gut infections by consumption of probiotics. A specific blend of probiotic lactic acid bacteria (Lactobacillus helveticus Rosell-52, Lactobacillus rhamnosus Rosell-11, Bifidobacterium longum Rosell-175) and a probiotic yeast (Saccharomyces boulardii), improved stool consistency and shortened the duration of diarrhea in a rat model of E.coli-induced diarrhea. These probiotics showed synergistic effects compared with administration of solely S. boulardii or a mixture of L. helveticus Rosell-52, L. rhamnosus Rosell-11, B. longum Rosell-175. Consumption of S. boulardii and a combination of L. helveticus Rosell-52, L. rhamnosus Rosell-11 reduced diarrhea in humans. Aim: To study whether probiotics improves the resistance of humans to enterotoxigenic E. coli (ETEC). Study design: The PROTETEC study is a parallel, double-blind, placebo-controlled 4-weeks intervention with probiotics in healthy volunteers. In this study, the effect of probiotic intervention vs placebo on several infection markers in response to an ETEC challenge is investigated. Participants will be randomly assigned to the probiotic or placebo group (n=30 per group). Subjects will be instructed to maintain their usual pattern of physical activity and their habitual food intake, but to standardize their dietary calcium intake. After an adaptation period of 2 weeks, subjects will be orally infected with a live, but attenuated, ETEC vaccine (strain E1392-75-2A; collection NIZO food research; dose 10E10 CFU). Before and after infection, a diary will be kept to record all food and drinks consumption (2x2 days) to assess the habitual dietary intake, as well as for daily recording of bowel habits and frequency and severity of gastrointestinal complaints. The following biological samples will be collected: 4x10 ml venous blood, a single fecal bolus (for screening) and 7x24 hrs feces. Blood is sampled for immune response analyses and the fecal samples are collected to quantify several infection- and immune system markers, to determine probiotic excretion, and to verify dietary calcium intake. Study population: Healthy males of 20-55 yrs of age. Interventions: Probiotics (capsules containing freeze-dried powder, probiotic dose per capsule 5x10E9 CFU; twice daily) or placebo (capsules with carrier material powder of identical appearance) Primary outcomes: Fecal ETEC excretion and severity of diarrhea (quantified by fecal output per day). Secondary outcomes: Serum immune response to ETEC, self-reported stool consistency scores and gastrointestinal complaints, relative fecal wet weight. Tertiary outcomes: sIgA and calprotectin in feces, probiotic persistence and levels of opportunistic pathogens in the endogenous microbiota.

Conditions

Gastroenteritis; Bacterial Infection; Diarrhea

Outcome Measures

Primary Outcomes (2)

• Fecal ETEC excretion curve over time as marker of the colonization resistance

  The curve of fecal ETEC excretion over time is compared between verum and placebo group.

  Fecal ETEC excretion measured 1-2 days before ETEC infection, and on day 1, 2, 3, 4, 7 and 15 after infection.

• Total daily fecal output curve over time as marker of diarrhea

  The curve of daily fecal output over time is compared between verum and placebo group.

  Daily fecal output is measured 1-2 days before ETEC infection (baseline), and on day 1, 2, 3, 4, 7 and 15 after infection.

Secondary Outcomes (4)

• Bowel habits

  Scored daily in a diary during 4 weeks, starting at the day of dietary intervention until 2 weeks after ETEC infection.

• Frequency and severity of gastrointestinal symptoms

  Scored daily by VAS scores in a diary during 4 weeks, starting at the day of dietary intervention until 2 weeks after ETEC infection.

• Diarrhea severity

  1-2 days before ETEC infection, and on day 1, 2, 3, 4, 7 and 15 after infection.

• Specific serum antibody response to CFA-II

  Before and at day 3 and 15 after ETEC infection.

Other Outcomes (3)

• Opportunistic pathogens in feces

  1-2 days before ETEC infection, and on selected time points after infection (day 1, 2, 3, 4, 7 or 15, depending on results of primary and secondary outcomes).

• Calprotectin in feces

  1-2 days before ETEC infection, and on selected time points after infection (day 1, 2, 3, 4, 7 or 15, depending on results of primary and secondary outcomes).

• Total faecal sIgA

  1-2 days before ETEC infection, and on seleceted time points after infection (day 1, 2, 3, 4, 7 or 15, depending on results of primary and secondary outcomes).

Study Arms (2)

Probiotics

EXPERIMENTAL

Capsule containing 5x10E9 CFU probiotics. Twice daily for 2 weeks.

Dietary Supplement: Probiotics

Placebo

PLACEBO COMPARATOR

Capsule containing carrier material powder of identical appearance. Twice daily for 2 weeks.

Dietary Supplement: Placebo

Interventions

Probiotics DIETARY_SUPPLEMENT

Probiotics

Placebo DIETARY_SUPPLEMENT

Placebo

Eligibility Criteria

• Age: 20 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Signed informed consent
• Male
• Age 20-55 yrs
• Availability of internet connection
• Willingness to replace habitual dairy product intake with the supplied low-calcium soy products
• Willingness to abstain from products with high amounts of prebiotic fibers and from products with probiotics (except for the supplied one) starting 1 month prior to study start
• Willingness to give blood donation from 1 month before the start of the experiment and during the entire experimental period.

You may not qualify if:

• Current or previous underlying disease of the GI tract, liver, bile bladder, kidney, thyroid gland (self-reported)
• Allergy to milk products or lactose intolerance (self-reported), since the capsules may contain milk traces from culture media
• Allergy to soy products (self-reported)
• High titer serum antibodies against ETEC (10 ml blood sample collected at screening)
• Vegetarians
• Vegans
• Heavy alcohol use (\>4 consumptions/day or \>20/week)
• Drug use

Sponsors & Collaborators

• NIZO Food Research: lead
• Lallemand Health Solutions: collaborator

Study Sites (1)

NIZO Food Research

Ede, Utrecht, 6718 ZB, Netherlands

Location

Related Publications (1)

• Ten Bruggencate SJ, Girard SA, Floris-Vollenbroek EG, Bhardwaj R, Tompkins TA. The effect of a multi-strain probiotic on the resistance toward Escherichia coli challenge in a randomized, placebo-controlled, double-blind intervention study. Eur J Clin Nutr. 2015 Mar;69(3):385-91. doi: 10.1038/ejcn.2014.238. Epub 2014 Nov 5.

  PMID: 25369827 RESULT

MeSH Terms

Conditions

Gastroenteritis; Bacterial Infections; Diarrhea

Interventions

Probiotics

Condition Hierarchy (Ancestors)

Gastrointestinal Diseases; Digestive System Diseases; Bacterial Infections and Mycoses; Infections; Signs and Symptoms, Digestive; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Dietary Supplements; Food; Diet, Food, and Nutrition; Physiological Phenomena; Food and Beverages

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 11, 2012
• First Posted: October 18, 2012
• Study Start: August 1, 2012
• Primary Completion: November 1, 2012
• Study Completion: November 1, 2012
• Last Updated: August 27, 2015

Record last verified: 2015-08

Locations

NL (1)